<DOC>
	<DOCNO>NCT00821483</DOCNO>
	<brief_summary>The purpose study : 1 . To compare efficacy single dose Frovatriptan 2.5 mg placebo acute treatment one migraine attract 2 . To assess recurrence rate two group 3 . To assess safety tolerability</brief_summary>
	<brief_title>A Double Blind Placebo-controlled , Parallel Group Study Assess Efficacy Safety Frovatriptan Acute Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>1 . Adults age 18 65 year 2 . The patient must history migraine accord criterion Headache Classification Committee International Headache Society ( IHS ) , previous 1 year . The patient must experience one eight moderate severe migraine attack ( without aura ) month least previous two month 3 . Onset migraine disease must occur patient 50 year age 4 . Able willing sign inform consent , able willing comply study procedure , include completion diary card . 1 . Pregnant lactating female , woman intend become pregnant breast feed study period , woman childbearing potential use adequate contraception . Females reproductive potential must negative pregnancy test screen 2 . Clinically significant renal dysfunction ( creatinine≥2.0mg/dl ) hepatic dysfunction ( ALT , AST≥2 ULN ) 3 . Patients clinically significant abnormal ECGs rest diastolic blood pressure 95mmHg 4 . Patients clinically significant cardiovascular cerebrovascular disease 5 . Patients history clinically relevant allergy , include allergy triptan 6 . Previous treatment Frovatriptan time treatment investigational drug within 30 day screen visit 7 . Patients diagnosis vertebrobasilar hemiplegic ( prolonged atypical aura ) migraine ( IHS criterion ) 8 . Potentially uncooperative patient , unable provide inform consent , unable complete diary 9. patient habitually abuse headache medication include ergotaminecontaining compound , patient history alcohol and/or medicine abuse , Investigator 's opinion 10 . Patients able tell migraine headache 11 . Patients 15 headache day per month , average , take symptomatic medication headache two day per week , average 12 . Treatment monoamineoxidase inhibitor ( MAOI ) within two week screen visit 13 . Patients take prophylactic migraine medication , unless dose stabilized 30 day expect continue duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>